Xu Zhifeng, Zhang Yuanyuan, Zhang Chun, Xiong Fei, Zhang Jianduan, Xiong Jing
1Department of Nephrology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
2Department of Maternal and Child Health, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Aging Dis. 2022 Jun 1;13(3):884-898. doi: 10.14336/AD.2021.1125. eCollection 2022 Jun.
COVID-19 emerged in Wuhan in December 2019 and soon became a worldwide pandemic. We collected and analyzed the data from 1077 patients with COVID-19 who were admitted to the west campus of Wuhan Union Hospital from January 16 to April 16, 2020. Sixty (5.6%) of the 1077 COVID-19 patients were diagnosed with acute kidney injury (AKI) during hospitalization, and 18 of them (30%) had AKI on chronic kidney disease (AKI/CKD). COVID-19 patients with AKI had a worse prognosis, with higher intensive care unit (ICU) admission (28.3%) and fatality (65%) rates than patients without AKI (3.4% and 10.7%, respectively). Among the COVID-19 patients, AKI was more likely to occur in male patients, the elderly, patients with more severe disease states and those with comorbidities (such as hypertension, diabetes, coronary heart disease (CHD), chronic obstructive pulmonary disease (COPD) and CKD). COVID-19 patients with AKI were more likely to develop respiratory failure, gastrointestinal bleeding, acute liver injury, acute myocardial injury, heart failure, acute respiratory distress syndrome (ARDS), cerebrovascular accident, and disseminated intravascular coagulation (DIC) than those without AKI. Compared with patients without AKI, COVID-19 patients with AKI had lower platelet counts, lymphocyte counts, albumin levels and serum calcium levels but had elevated leukocyte counts, neutrophil counts and serum potassium levels. Inflammatory indicators, such as C-reactive protein (CRP), interleukin-6 (IL-6), and procalcitonin (PCT), were significantly higher in patients with AKI than in those without AKI. COVID-19 patients with AKI also exhibited a longer prothrombin time (PT), a longer activated partial thromboplastin time (APTT), and a higher D-dimer level than those without AKI. Survival analysis revealed that COVID-19 patients with AKI had a reduced survival rate compared with those without AKI. Furthermore, COVID-19 patients with AKI/CKD had a lower survival rate than those with AKI or CKD only. Multiple logistic regression indicated that the predictors of AKI in COVID-19 patients included complications, such as respiratory failure and acute myocardial injury, and higher creatinine and PCT levels during hospitalization.
2019年12月新型冠状病毒肺炎(COVID-19)在武汉出现,并很快成为全球大流行疾病。我们收集并分析了2020年1月16日至4月16日期间收治于武汉协和医院西院区的1077例COVID-19患者的数据。1077例COVID-19患者中有60例(5.6%)在住院期间被诊断为急性肾损伤(AKI),其中18例(30%)为慢性肾脏病基础上的急性肾损伤(AKI/CKD)。与无AKI的COVID-19患者相比,发生AKI的COVID-19患者预后更差,重症监护病房(ICU)入住率(分别为28.3%和3.4%)和病死率(分别为65%和10.7%)更高。在COVID-19患者中,AKI更易发生于男性、老年人、病情更严重的患者以及合并症患者(如高血压、糖尿病、冠心病(CHD)、慢性阻塞性肺疾病(COPD)和CKD)。与无AKI的COVID-19患者相比,发生AKI的COVID-19患者更易出现呼吸衰竭、消化道出血、急性肝损伤、急性心肌损伤、心力衰竭、急性呼吸窘迫综合征(ARDS)、脑血管意外和弥散性血管内凝血(DIC)。与无AKI的患者相比,发生AKI的COVID-19患者血小板计数、淋巴细胞计数、白蛋白水平和血清钙水平更低,但白细胞计数、中性粒细胞计数和血清钾水平升高。炎症指标,如C反应蛋白(CRP)、白细胞介素-6(IL-6)和降钙素原(PCT),在AKI患者中显著高于无AKI的患者。发生AKI的COVID-19患者的凝血酶原时间(PT)更长、活化部分凝血活酶时间(APTT)更长,D-二聚体水平也高于无AKI的患者。生存分析显示,与无AKI的COVID-19患者相比,发生AKI的患者生存率降低。此外,AKI/CKD的COVID-19患者的生存率低于仅患有AKI或CKD的患者。多因素logistic回归分析表明,COVID-19患者发生AKI的预测因素包括呼吸衰竭和急性心肌损伤等并发症以及住院期间更高的肌酐和PCT水平。